1
|
Kent S, Jeha GM, Qiblawi S, Malinosky H, Greenway HT, Kelley B. Hidradenocarcinoma: A Case Series From the Scripps Clinic With a Systematic Review of the Literature. Dermatol Surg 2024; 50:507-511. [PMID: 38460197 DOI: 10.1097/dss.0000000000004140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2024]
Abstract
BACKGROUND Hidradenocarcinoma (HAC) is a rare adnexal carcinoma. To the best of the authors' knowledge, there are no published systematic reviews on HAC. OBJECTIVE To incorporate a case series from the authors' institution and systematically integrate reported information to provide a reference tool for optimization of diagnosis and management. METHODS A comprehensive MEDLINE search was conducted from database inception to 2021 using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This yielded 225 studies with 165 cases of HAC. References of included articles were also searched. In addition, 9 patients with HAC were identified from the authors' institution over the past 10 years. RESULTS The mean age of HAC presentation is 60 years with a slight male predilection (60%). The head and neck is the most commonly affected region. Over 36% of cases either presented with metastatic disease or went on to metastasize. The most common treatment type was wide local excision, followed by Mohs micrographic surgery. CONCLUSION Early detection with accurate histologic interpretation is prudent in all cases of HAC. Wide local excision is the current first-line treatment. However, Mohs micrographic surgery offers complete marginal analysis with evidence of reduced risk of metastasis and better outcomes compared with wide local excision. Currently, there are no National Comprehensive Cancer Network guidelines for the treatment of HAC, and consensus guidelines are limited to tumor and nodal metastasis staging provided by the American Joint Committee on Cancer, eighth edition. Thus, this case series and systematic review integrates important aspects of diagnosis, workup, and management of HAC.
Collapse
Affiliation(s)
- Steven Kent
- Bighorn Mohs Surgery and Dermatology Center, Scripps Clinic, La Jolla, CA
| | - George M Jeha
- Louisiana State University Health Sciences Center, New Orleans, LA
| | | | - Hannah Malinosky
- Louisiana State University Health Sciences Center, New Orleans, LA
| | | | - Benjamin Kelley
- Louisiana State University Health Sciences Center, New Orleans, LA
| |
Collapse
|
2
|
Elouaouch S, El Youssi Z, Mansouri H, Nadir M, Bennani A, Guerrouaz MA, Moukhlissi M, Berhili S, Mezouar L. Localized Hidradenocarcinoma of the Scalp: A Case Report. Cureus 2023; 15:e38675. [PMID: 37288227 PMCID: PMC10243552 DOI: 10.7759/cureus.38675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/07/2023] [Indexed: 06/09/2023] Open
Abstract
Hidradenocarcinomas or malignant hidradenomas are tumors developed from the sweat glands, in particular, the eccrine glands. It is a rare entity of skin tumors and frequently appears de novo with a slight female predominance and an average age of 50 years at diagnosis. We report the case of a 57-year-old woman treated for localized hidradenocarcinoma of the scalp, successfully managed by surgery and adjuvant radiotherapy.
Collapse
Affiliation(s)
- Sofia Elouaouch
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Zahira El Youssi
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Hanane Mansouri
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Miry Nadir
- Anatomopathology, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Amal Bennani
- Anatomopathology, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | | | - Mohamed Moukhlissi
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Soufiane Berhili
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| | - Loubna Mezouar
- Radiation Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR
| |
Collapse
|
3
|
Buffo TH, Stelini RF, Serrano JYM, Pontes LT, Magalhães RF, de Moraes AM. Mohs micrographic surgery in rare cutaneous tumors: a retrospective study at a Brazilian tertiary university hospital. An Bras Dermatol 2023; 98:36-46. [PMID: 36369200 PMCID: PMC9837646 DOI: 10.1016/j.abd.2022.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 12/13/2021] [Accepted: 01/07/2022] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Mohs micrographic surgery is an established technique in the treatment of cutaneous neoplasms. It offers higher cure rates and the main indications are non-melanoma malignant skin tumors. Few studies have been performed on the treatment of rare tumors through this technique. OBJECTIVE To study rare skin tumors and rare variants of basal cell carcinoma and squamous cell carcinoma submitted to Mohs micrographic surgery in a tertiary service in relation to frequency, disease-free evolution, and applicability of this surgical procedure for this group of tumors. METHODS This was a retrospective observational study including rare skin tumors and less common variants of basal cell carcinoma and squamous cell carcinoma treated using Mohs micrographic surgery, between October 2008 and April 2021. RESULTS During the study period, 437 tumors were treated using Mohs micrographic surgery, and 22 (5%) rare skin tumors were selected. The tumors comprised three dermatofibrosarcomas protuberans, two atypical fibroxanthomas, two spiradenomas, two hypercellular fibrohistiocytomas, one primary cutaneous adenocarcinoma, one trichoblastoma, one porocarcinoma, one chondroid syringoma, one cutaneous angiosarcoma, one Merkel cell carcinoma, and one sebaceous carcinoma. Six other cases of rare basal cell carcinoma variants with trichoepitheliomatous differentiation, metatypical basal cell carcinoma, and clear cell squamous cell carcinoma were included. There were no cases of recurrence after an average of six years of follow-up. STUDY LIMITATIONS This is a retrospective study on rare neoplasms carried out in a single referral center, and this surgical technique isn't widely available in the public service. CONCLUSION This retrospective case series showed that Mohs micrographic surgery is an appropriate treatment for rare skin tumors. They corresponded to 5% of the tumors treated by the technique during a 12-year-period, with no recurrences identified.
Collapse
Affiliation(s)
- Thais Helena Buffo
- Discipline of Dermatology, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil,Corresponding author.
| | - Rafael Fantelli Stelini
- Department of Pathological Anatomy, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil
| | | | - Luciana Takata Pontes
- Discipline of Dermatology, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil
| | - Renata Ferreira Magalhães
- Discipline of Dermatology, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil
| | - Aparecida Machado de Moraes
- Discipline of Dermatology, Faculty of Medical Sciences, Universidade Estadual de Campinas, Campinas, SP, Brazil
| |
Collapse
|
4
|
Rafols M, Mejia O, Oh KS, Bendixen B, Jorge I, Narayanan S. An Unusual Case of Lower Extremity Clear Cell Hidradenocarcinoma. Case Rep Surg 2020; 2020:6192109. [PMID: 32328335 PMCID: PMC7171610 DOI: 10.1155/2020/6192109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 03/17/2020] [Indexed: 11/29/2022] Open
Abstract
Hidradenocarcinoma (HC) is a rare malignant sweat gland tumor with metastatic potential primarily located in the head, neck, and trunk. We present an unusual case of a large lower extremity Clear Cell HC managed with surgical resection and adjuvant locoregional radiation after excluding lymph node involvement.
Collapse
Affiliation(s)
- Marc Rafols
- Department of General Surgery, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
| | - Odille Mejia
- Department of Pathology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
| | - Kei Shing Oh
- Department of Pathology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
| | - Blake Bendixen
- Florida International University Herbert Wertheim College of Medicine, Miami, FL 33199, USA
| | - Irving Jorge
- Department of General Surgery, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
| | - Sumana Narayanan
- Department of Surgical Oncology, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA
| |
Collapse
|
5
|
Kane B, Adler E, Bhandari T, Rose M, DiGuglielmo N, Sun X. Malignant Hidradenocarcinoma in the Lower Extremity: A Case Report of a Rare Tumor. J Foot Ankle Surg 2018; 57:618-621. [PMID: 29472169 DOI: 10.1053/j.jfas.2017.10.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Indexed: 02/03/2023]
Abstract
Malignant hidradenocarcinomas are rare soft tissue tumors of sweat gland origin. We present the case of a soft tissue, fungating tumor of 15 years' duration of the medial ankle in an 85-year-old male that exhibited malignant features clinically and radiographically. Subsequent punch biopsy revealed a diagnosis of malignant hidradenocarcinoma. Given the risk of recurrence and the poor radiation and chemotherapy options, the patient initially decided to leave the lesion untreated. However, he soon developed lower extremity cellulitis from the exposed lesion and decided to have the tumor excised, eliminating the source of the infection. In the present case study, we discuss the etiology, clinical and radiographic characteristics, and treatment options for this rare lesion. At the 18-month follow-up visit, he had had no recurrence of the lesion.
Collapse
Affiliation(s)
- Brendan Kane
- Podiatry Resident Postgraduate Year 3, Jersey Shore University Medical Center, Neptune, NJ.
| | - Evan Adler
- Podiatry Attending Physician, Adler Foot and Ankle, Oakhurst, NJ
| | - Tarun Bhandari
- General Surgeon - Oncology, Atlantic Shore Surgical Associates, Brick, NJ
| | - Michael Rose
- Plastic Surgeon, The Plastic Surgery Center, Shrewsbury, NJ
| | | | - Xiu Sun
- Pathologist, Jersey Shore University Medical Center, Neptune, NJ
| |
Collapse
|
6
|
Giannelli F, Chiola I, Belgioia L, Garelli S, Pastorino A, Marcenaro M, Mammoliti S, Costantini S, Bizzarri N, Vellone V, Barra S, Corvò R. Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report. J Contemp Brachytherapy 2017; 9:572-578. [PMID: 29441103 PMCID: PMC5807991 DOI: 10.5114/jcb.2017.71554] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Accepted: 10/04/2017] [Indexed: 11/23/2022] Open
Abstract
Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 - PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.
Collapse
Affiliation(s)
| | - Ilaria Chiola
- Health Science Department (DISSAL), University of Genova
| | - Liliana Belgioia
- Radiation Oncology Department, Policlinico San Martino Hospital
- Health Science Department (DISSAL), University of Genova
| | | | | | | | | | | | | | - Valerio Vellone
- Pathological Anatomy Department, Policlinico San Martino Hospital, Genova, Italy
| | - Salvina Barra
- Radiation Oncology Department, Policlinico San Martino Hospital
| | - Renzo Corvò
- Radiation Oncology Department, Policlinico San Martino Hospital
- Health Science Department (DISSAL), University of Genova
| |
Collapse
|
7
|
Abstract
BACKGROUND Adnexal carcinomas (ACs) are rare cutaneous malignancies of sweat gland or pilosebaceous origin. Optimal treatment and metastatic potential of AC are poorly defined. Mohs micrographic surgery (MMS) has been increasingly used to treat AC. OBJECTIVE To review selected primary cutaneous AC and their treatment outcomes with MMS. MATERIALS AND METHODS Literature review using PubMed search for articles related to primary cutaneous ACs. RESULTS Sebaceous carcinoma treated with MMS recurred and metastasized in 6.4% and 3.7%, respectively. Primary cutaneous mucinous carcinoma treated with MMS recurred and metastasized in 9.6% and 6.4%, respectively. After MMS, 4.7% of microcystic AC recurred with no reported metastases. After MMS, recurrences and metastases of trichilemmal carcinoma or hidradenocarcinoma have not been reported. Two (4.2%) regional lymph node metastases but no distant metastases or local recurrences have been reported in eccrine porocarcinoma. Squamoid eccrine duct tumor, pilomatrix carcinoma, and spiradenocarcinoma treated with MMS are also reviewed. CONCLUSION The rarity of ACs and the lack of comparative data on treatment makes conclusive recommendations on treatment difficult. Recent large case series and reviews suggest MMS is a useful and possibly superior treatment for AC and should be considered if primary cutaneous disease is suspected.
Collapse
|
8
|
Labbardi W, Hali F, Marnissi F, Cribier B, Chiheb S. [Hidradenocarcinoma of the heel associated with inguinal metastases]. Ann Dermatol Venereol 2017; 144:536-542. [PMID: 28528731 DOI: 10.1016/j.annder.2017.03.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2016] [Revised: 10/28/2016] [Accepted: 03/03/2017] [Indexed: 01/14/2023]
Abstract
BACKGROUND Hidradenocarcinoma is a rare malignant tumour involving the sweat glands. It classically arises de novo, only rarely resulting from pre-existing hidradenoma. The literature contains few reports of lymph node metastasis in this tumour. We report a case of a patient with hidradenocarcinoma of the heel associated with inguinal node metastases. PATIENTS AND METHODS We report the case of a 64-year-old patient with a history of chronic smoking, who in the last two years developed a painless nodule in his right heel, with no prior injury, and which gradually increased in size to become an ulcerated tumour. Physical examination revealed a rounded tumour mass, ulcerated in the centre, and associated with multiple inguinal adenopathies. Histological and immunohistochemical examination was suggestive of hidradenocarcinoma. The patient had undergone extensive local excision with inguinal lymphadenectomy. Histological examination showed infiltration of lymph nodes by the tumour with capsular rupture. Radiotherapy was subsequently given. The outcome was good without recurrence after 34 months of follow-up. DISCUSSION Hidradenocarcinoma is a rare malignant tumour. Diagnosis is based on histological and immunohistochemical examination. However, hidradenocarcinoma may on occasion be difficult to differentiate from hidradenoma, a benign tumour, hence the interest of complete surgical resection with safety margins even in the absence of cytological malignancy. Local recurrences are common. The occurrence of lymph node metastasis during hidradenocarcinoma has been described only rarely in the literature. Such metastases usually occur after tumour resection. The specific features of our case are the rarity of lymph node metastases in hidradenocarcinoma coupled with the fact that these metastases were discovered upon diagnosis of the primary tumour.
Collapse
Affiliation(s)
- W Labbardi
- Service de dermatologie, CHU d'Ibn-Rochd, Casablanca, Maroc.
| | - F Hali
- Service de dermatologie, CHU d'Ibn-Rochd, Casablanca, Maroc
| | - F Marnissi
- Service d'anatomopathologie, CHU d'Ibn-Rochd, Casablanca, Maroc
| | - B Cribier
- Clinique dermatologique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - S Chiheb
- Service de dermatologie, CHU d'Ibn-Rochd, Casablanca, Maroc
| |
Collapse
|
9
|
Miller DH, Peterson JL, Buskirk SJ, Vallow LA, Ta R, Joseph R, Krishna M, Ko SJ, Tzou KS. Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation. Rare Tumors 2015; 7:6082. [PMID: 26500736 PMCID: PMC4600998 DOI: 10.4081/rt.2015.6082] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Accepted: 06/25/2015] [Indexed: 11/30/2022] Open
Abstract
Hidradenocarcinoma is a rare aggressive form of cutaneous adnexal skin carcinoma originating from the sweat gland. Due to its low incidence, prognostic and treatment strategies are still being explored both for primary and advanced disease. This tumor most often presents as either solid or cystic appearing subcutaneous nodules, which may be associated with pruritus or ulceration. To date the mainstay of treatment for local disease has been surgical excision; however, the paucity of historical data available has shown that these tumors often behave aggressively with high rates of local recurrence, metastasis, and poor overall outcomes. There are few case reports describing the utility of radiation therapy in the treatment of hidradenocarcinoma. Herein, we present a case of metastatic apocrine hidradenocarcinoma in a 32-year-old Caucasian male. The patient initially underwent excisional biopsy which confirmed the diagnosis of poorly differentiated, highly infiltrative, apocrine hidradenocarcinoma. He received systemic chemotherapy for metastatic disease, followed by radiation therapy to areas of grossly palpable adenopathy. Prior to radiation therapy the patient had an enlarged hypermetabolic conglomerate of lymph nodes in the right axilla, and borderline enlarged low activity nodes within the left axilla. He received 3 cycles of chemotherapy followed by tamoxifen and radiation therapy (50.4 Gy in 28 fractions) to areas of progressive disease in the bilateral axilla, lower neck, and axillary skin. Following treatment, the patient had complete resolution of skin nodules and improvement of his pruritus. While the role of radiation therapy in the treatment of hidradenocarcinoma has not been well established, this case report demonstrated the potential benefit of external beam radiotherapy in the management of this rare disease.
Collapse
Affiliation(s)
- Daniel H Miller
- Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL, USA
| | | | - Steven J Buskirk
- Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL, USA
| | - Laura A Vallow
- Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL, USA
| | - Randy Ta
- University of Minnesota , Minneapolis, MN, USA
| | - Richard Joseph
- Department of Hematology/Oncology, Mayo Clinic , Jacksonville, FL, USA
| | - Murli Krishna
- Department of Laboratory Medicine and Pathology, Mayo Clinic , Jacksonville, FL, USA
| | - Stephen J Ko
- Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL, USA
| | - Katherine S Tzou
- Department of Radiation Oncology, Mayo Clinic , Jacksonville, FL, USA
| |
Collapse
|
10
|
Mohs micrographic surgery for the treatment of hidradenocarcinoma: the Mayo Clinic experience from 1993 to 2013. Dermatol Surg 2015; 41:226-31. [PMID: 25627632 DOI: 10.1097/dss.0000000000000242] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Hidradenocarcinoma (HAC) is a rare malignant adnexal neoplasm with reported metastatic potential and undefined optimal treatment. OBJECTIVE To review clinical characteristics and outcomes of patients with HAC treated with Mohs micrographic surgery (MMS). MATERIALS AND METHODS The authors performed a retrospective chart review of patients with HAC treated by MMS at Mayo Clinic from 1993 to 2013, recording patient demographics, tumor characteristics, MMS stages to clearance, follow-up, recurrence, metastasis, and mortality. RESULTS Ten patients underwent MMS for HAC more than 20 years. The average age was 62.8 years, with 6 females and 4 males. Occipital scalp was the most common location (40%), followed by extremities (30%) and face (20%). In 5 of 7 cases (71%), "cyst" was the working clinical diagnosis. The average preoperative lesion area was 3.18 cm, with an average of 1.5 MMS stages required for clearance. Mean postoperative follow-up was 7 years (range, 5-205 months). No tumors treated with MMS recurred, metastasized, or led to disease-related mortality. CONCLUSION Mohs micrographic surgery seems to be a useful treatment modality for HAC. This is the largest reported series of HAC treated with MMS with long-term follow-up.
Collapse
|
11
|
Soni A, Bansal N, Kaushal V, Chauhan AK. Current management approach to hidradenocarcinoma: a comprehensive review of the literature. Ecancermedicalscience 2015; 9:517. [PMID: 25815059 PMCID: PMC4370612 DOI: 10.3332/ecancer.2015.517] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Indexed: 12/03/2022] Open
Abstract
Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.
Collapse
Affiliation(s)
- Abhishek Soni
- Department of Radiotherapy, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
| | - Nupur Bansal
- Department of Radiotherapy, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
| | - Vivek Kaushal
- Department of Radiotherapy, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
| | - Ashok Kr Chauhan
- Department of Radiotherapy, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
| |
Collapse
|
12
|
Gupta E, Guthrie KJ, Krishna M, Asmann Y, Parker AS, Joseph RW. Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature. Rare Tumors 2015; 7:5719. [PMID: 25918615 PMCID: PMC4387361 DOI: 10.4081/rt.2015.5719] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2014] [Revised: 11/17/2014] [Accepted: 11/18/2014] [Indexed: 12/16/2022] Open
Abstract
Hidradenocarcinoma is a rare malignancy of the sweat glands with only a few cases reported in literature. The management of these tumors is based on the extent of disease with local disease managed with surgical resection. These can tumors carry a high potential of lymphatic and vascular spread and local and distant metastases are not uncommon. Given the rarity of the tumor and lack of genetic and clinical data about these tumors, there is no consensus on the proper management of metastatic disease. Here in we report the first case of metastatic hidradenocarcinoma with detailed molecular profiling including whole exome sequencing. We identified mutations in multiple genes including two that are potentially targetable: PTCH1 and TCF7L1. Further work is necessary to not only confirm the presence of these mutations but also to confirm the clinical significance.
Collapse
Affiliation(s)
- Eva Gupta
- Division of Hematology and Oncology, Mayo Clinic , Jacksonville, FL, USA
| | | | - Murli Krishna
- Department of Pathology/Lab Medicine, Mayo Clinic , Jacksonville, FL, USA
| | - Yan Asmann
- Division of Cancer Biology, Mayo Clinic , Jacksonville, FL, USA
| | - Alexander S Parker
- Departments of Health Sciences Research and Medicine, Mayo Clinic , Jacksonville, FL, USA
| | - Richard W Joseph
- Division of Hematology and Oncology, Mayo Clinic , Jacksonville, FL, USA
| |
Collapse
|
13
|
Bhullar JS, Varshney N, Mervak T, Mittal V, Silapaswan S. Hidradenocarcinoma: A Sinister Diagnosis of a Suspected Benign Condition. Am Surg 2014. [DOI: 10.1177/000313481408001232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | - Neha Varshney
- Department of Surgery Providence Hospital and Medical Centers Southfield, Michigan
| | - Timothy Mervak
- Department of Surgery Providence Hospital and Medical Centers Southfield, Michigan
| | - Vijay Mittal
- Department of Surgery Providence Hospital and Medical Centers Southfield, Michigan
| | - Sumet Silapaswan
- Department of Surgery Providence Hospital and Medical Centers Southfield, Michigan
| |
Collapse
|
14
|
Sbai A, Ouabdelmoumene A, Naciri F, Elhfid M, Mezouar L. [Hidradenocarcinoma of the scalp: report of a case]. Pan Afr Med J 2014; 17:102. [PMID: 25018839 PMCID: PMC4081152 DOI: 10.11604/pamj.2014.17.102.3485] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Accepted: 12/09/2013] [Indexed: 11/15/2022] Open
Abstract
L'hidradénocarcinome est une tumeur annexielle maligne extrêmement rare. Caractérisée par la fréquence des récidives locorégionales et des métastases à distance. Le diagnostic histopathologique de malignité se fait sur des critères architecturaux et cytologiques particuliers .la chirurgie d'exérèse large représente l'essentiel du traitement. Une radiothérapie adjuvante s'avère obligatoire en cas de facteurs de récidive locale. Le curage ou la radiothérapie prophylactiques des aires ganglionnaires régionales non envahies pourraient jouer un rôle primordial dans la réduction du risque de récidives locorégionales.
Collapse
Affiliation(s)
- Ali Sbai
- Centre Régional d'Oncologie Hassan II, Oujda, Maroc
| | | | - Farid Naciri
- Centre Régional d'Oncologie Hassan II, Oujda, Maroc
| | - Mohammed Elhfid
- Centre Régional d'Oncologie Hassan II, Oujda, Maroc ; Faculté de Médecine et de Pharmacie, Université Mohammed Premier,Oujda, Maroc
| | - Loubna Mezouar
- Centre Régional d'Oncologie Hassan II, Oujda, Maroc ; Faculté de Médecine et de Pharmacie, Université Mohammed Premier,Oujda, Maroc
| |
Collapse
|
15
|
|
16
|
Shu K, Xiao Q, Büchele F, Zhang S, Jiang W, Lei T. Diagnosis and treatment of clear cell hidradenocarcinoma of the scalp. ACTA ACUST UNITED AC 2012; 32:931-936. [PMID: 23271300 DOI: 10.1007/s11596-012-1061-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Indexed: 11/30/2022]
Abstract
Clear cell hidradenocarcinoma (CCH) is an exceedingly rare and highly malignant tumor of the eccrine sweat glands. Its treatment is extremely difficult due to the characteristically aggressive clinical course including repeated local recurrence and uncontrollable distal metastasis coming along with a very poor prognosis. Most published case studies recommend a wide surgical excision followed by adjuvant conservative therapy, which is generally considered to be the standard treatment. Two cases of nodular CCH of the scalp either presenting as a singular primary lesion or at an already metastatic stage were analyzed retrospectively. Wide local excision of the tumor couldn't prevent the primary carcinoma from recurring and metastasizing. Both cases received various therapies but the results were unsatisfactory. Although most authors have recommended that early wide surgical excision of the tumor is a feasible therapeutic measurement, our results raise doubts on the efficacy of this treatment strategy. As alternative approaches (i.e. chemotherapy, radiotherapy) are similarly controversial, further studies and a wide exchange of clinical experiences are crucial.
Collapse
Affiliation(s)
- Kai Shu
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Qungen Xiao
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Fabian Büchele
- Lab of Molecular Neurosurgery, Stereotactic and Functional Neurosurgery of Albert-Ludwigs University, Freiburg, 79106, Germany
| | - Suojun Zhang
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Wei Jiang
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
| | - Ting Lei
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| |
Collapse
|
17
|
|
18
|
|